Skip to content

Released Nov 4, 2020, after the close

10-Q filed Nov 5, 2020, 36 days after period end · 0001564590-20-050755

Q3 2020 · 10-Q
Revenue$17.82M+45.2% vs Q3 2019+88.2% vs Q2 2020
Net Income$17.14MN/M vs Q3 2019−42.6% vs Q2 2020
EPS Diluted$0.45N/M vs Q3 2019−52.1% vs Q2 2020
Operating Income-$10,617,000N/M
Operating Cash Flowderived-$17,689,000N/M
Margins · derived
Operating margin-59.6%+44.2 pt vs Q3 2019
Net margin96.2%+201.3 pt vs Q3 2019

What the release said

The release

Same quarter

MetricQ3 2020Q3 2019Q3 2018Q3 2017
Revenue$17.82M$12.28M$7.84M$17.50M
Net Income$17.14M-$12.91M-$10.24M-$1.42M
EPS Diluted$0.45-$0.56-$21.26-$3.14

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR